Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)

• Intermediate risk prostate cancer patients will be eligible for this study. Risk groups will be assigned as per NCCN guidelines. Intermediate risk patients will be defined as:

  • PSA 10-20 ng/ml or
  • Gleason score = 7 or
  • Clinical stage T2b/T2c

• Additionally, patients will be required to meet the following criteria:

  • Age >18
  • KPS > 80
  • Prostate size \< 60cc
  • Presence of a prostatic lesion with maximum dimension of >/= 0.5cm and no more than two additional disease foci, each with a maximum dimension less than that of the dominant lesion.
  • International Prostrate Symptom Score \< 15
  • Subjects must fill out the standard MRI screening form and satisfy all MRI screening criteria

Exclusion Criteria:

• Prior androgen deprivation therapy for prostate cancer
• Evidence of metastatic disease on bone scan or MRI/CT
• MRI ineligibility due to the presence of a cardiac pacemaker, defibrillator or other implanted metallic or electronic device which is considered MR unsafe, severe claustrophobia or inability to lie flat for the duration of the study, etc.
• Metallic hip implant, metallic implant or device in the pelvis that might distort the local magnetic field and compromise quality of MP-MRI.
• Lateral pelvic separation greater than 50 cm and/or anterior-posterior separation greater than 35 cm which are incompatible with MRCAT reconstruction
• Contra-indications to receiving gadolinium contrast
• KPS \< 80
• Pelvic MRI or CT (MRI preferred) evidence of radiographic T3, T4 or N1 disease.
• Prior history of transurethral resection of the prostate
• Prior history of chronic prostatitis
• Prior history of urethral stricture
• Prior history of pelvic irradiation
• History of inflammatory bowel disease
• Unable to give informed consent
• Unable to complete quality of life questionnaires

• Abnormal complete blood count. Any of the following

  • Platelet count less than 75,000/ml
  • Hb level less than 10 gm/dl
  • WBC less than 3.5/ml
• Abnormal renal function tests (creatinine > 1.5)